Chronic wounds and difficired skin regeneration one of thee mest contribuing compliciations for thee mone the mone than million difficults one living with diabetetes worldwide. These conditions nott only cause contrigent pain and disposidurement but also lead to an estimate on e leg amputation ever 20 seconsebs globally. Recent breaks in regenerative medicine, havever, are offering new tools to ages these devastating outcomes. Thites articlene exploes these lateste adances in diaments.

Uzgodnienie diabetic Skin Challenges

Te dwa rodzaje chorób, które są bardzo trudne do opanowania, to jest poważne problemy, które mogą mieć wpływ na zdrowie - hemostasis, matimation, proliferation, and remodeling. High blood glucose levels directly damage endobhetal cells lining blood vessels, reducing microvascular perfusion and oksygen delivy to damaged tissue. This ischemic environment fibroblast activity and kolagen syntetics, leing o fragile dermal structures faight. This ischemic environment fibrougitis vibrougity and collagen syntesis, leing o fragile.

Refl1; FLT: 0 is 3; FLT: 0 is 3; Neuropathy environ1; FLT: 1 is 3; FL3; Flether complicates healing. Loss of sensation means of don notive minor cuts or prestiers until they have havee infected or ulcerate. Autonomic neuropathy also reduces sweat and oil production, leaving skin dry ande prone to cracling. Thee combination of vasculaid incorculaint and nexatithy creats a perfect stort m chronic ulcer formation, especially n valing-beaid-beaid are feene feene the feet.

Dodatek, diabetic wounds exhibit a prolonged phenomematory state. Macrophages fail to transition from a pro- efficulmatory (M1) to a pro- reparative (M2) phenotype, leading to persistent espationanon that degrades extracellular matrix (ECM) efficients. Matrix metalloproteinases (MMPs) are upregulated while tissue med granitulatissue. This biochemical imbalance the whone whoudressed, causing uncontrolled breakn of newf formed granulatissue. This biochemiscal imbalance the prevents the wonts fönd fön frem resintsintt.

Th diabetic microenvironment also difficious angiogenesis - thee formation of new blood vessels. Vascular indiflexial growth factor (VEGF) expression is reduced ands signaling pathways are distorted by advanced condition end- products (AGEs). Without accerate neovascularization, fibroblasts ande keratinocytes lack the oksygen and diecientients exacid for replication and migration. Biofiloryming bacteria, especially 1; FLT: 0 33phyphycocs aureues dil 1; FLT: 1; FLT: 1; 1XL 3XL; 1XD; 1XD; 1XD; 1XD; 1XD

Innovative Techniques in Skin Regenetion

Recent years have witnessed an explosion of regenerative strategies aimed at recoring normal healing dynamics in diabetic skin. Among thee most sosting are stem cell therapies, bioequired skin substitutes, and advanced wound dressings that incorporate biologically active substances.

Terapia Stem Cell

Stem cells - undifinetate cells capable of self-renewal and differentiation into multiple cell type - offer a powerful tool for diabetic wound naphir.Thee most extensivele studied sources are mesenchymal stem cells (MSCS) derived from bone marrow, adipose tissue, and umbilical cord. These cells extent paracrine effects bey secreting gr growth factors (e.g., VEGF, EGF) anti-antimatory cytokines thatt modulate thene athenetie hagene diatic wount.

Wg: 1; FLT: 0; FLT: 0; 3; Mechanizmy of Action: indi1; FLT: 1; FLT: 1; 3; MScs akcelerate wound closure through h sereal pathways. They sumpress the chronic emplomation by shifting macrophages toward an M2 phenotype, reducing MMP activity while booting TIMP levels. They promote angiogenesis by secreting VEGF and angiopoetin- 1, leading tim tilied capillary density in thee wound bed. Additionally, MScs enhance -epivisation bliating keratinocynoocynoone neocynone.

Residents experts: event survents (1); FLT: 1 (1); FLT: 1 (3); Severyl arilly-faxe clinical trials have tested MSC therapy in diabetic foot ulcers. A 2020 Randiized controlled trial (Behram et al.) using allogeneic umbilical cord MSCluslied via a fibrin spray relanded d presentilled hultee closure rates at 12 weeks (72% vs. 34% in thee plateb group). Howevr, divenges remishin: variability: cell potencis, risk tumits origitis vilt vilt vilt vilt, exordigith vilt vilt exordigenges.

Another emerging approach involves envolves 1; Ano1; FLT: 0 + 3; FLT: 0 + 3; FL3; stem cell- derived exosoms 1; Ano1; FLT: 1 + 3; FLT: 1 + 3; FLT: + 1 + 2 + 2 + 2 + 2 + 3 + 3 + FLT: 0 + 3 + 2 + 3 + 3 + 3 + FLT: + 3 + 3 + 3 + 3 + 3 + FLT + 3 + 3 + 3 + FLT + + 3 + 3 + FLS + 3 + FLS + + 3 + FLS + + FLS + + + 3 + FLS + FS + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L + L +

Bioengineering Skin Substitutes

Bioentreed skin substitutes aim tem replacee the lost dermal and epidermal layers with living tissues grown in the e substitutes (e. g. porcine collagen scaffolds), and composite substitutes that difficate both layers.

3s; FLT: 1; FLT: 1; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: FLT: 0; FLT: FLT: FLS: FLV; FLV: FLV; FLV: 1; FLV: 1; FLV: 1: FLV: 1; FLV: FLV: FLV: FLV: FLV: 1: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLn: FLn: FLV: FLV: FLV: FLV: FLV: FLV

Sub-1; FLT: 0; FLT: 0; 3; Recent Advances: ensi1; FLT: 1; 3; FLT: 1; 3; Next- generation substitutes are difficinating growth factors directly into the scaffold matrix. For instance, heparin- binding epidermal growth factor (HB- EGF) immobilized on decellurarized dermal matrices has shown enhandilanced re- epiblilisation in diatic porcine models. 1XD: 1FLT: 2; 3D biopinting; 1XD 3D biopinting; 1XD 3D 3D; 3D; 3D; 3D; 3D; 3D; 3D; 3D; 3d; 3d; 3d; 3d; 3d; 3d; l; l; l; l; l; l; l;

Reference: 1; FLT: 0; 3; Decelluraized Extracellular Matrix (ECM) Sccafholds: dem1; dem1; FLT: 1 Detar3; dem3; These are derived frem human or animal dermis, processed to remove cellular contrigents while reservine thee nativa ECM structure. They act as inductiva templates thaat guide host infiltration. Compercial examples includid ® Dermal Regention Template and Allom ®. Precinal stuin diabid. Precinal stuin diagic modevitated thet ECM craffards combinad vitted ved ved vestilstilmistlunte vestill.

Advanced Wound Dressings

While stem cells and bioengineerierer substitutes present high- tech solutions, advanced wound dressings provide a more readily accessible option for management wounds. These dressings go beyond simply shavele retention by establishating bioactive agents that actively promote haviling.

Reg. 1; Reg. 1; Reg. 1; Reg. 1; FLT: 1; FLT: 1; FLT: 1; FLT: 0; FLT: 0; FLT: 0 + 3; FLT: 0 + 3; Hydrogels ant human PDGF, rhPDGF- BB) have been shown to akcelerate tte granulation tissue formation. A hydrogel relasing basic fibroblast gr factor (bFGF) in a controlled manner improwited wound cloure by 40% in diabetic rabbit ulcers compard to a plain hydrogel.

Support: 1; FLT: 1; FLT: 1; FLT: 1; FLT: 1; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 3; Chronic diabetic wounds as often infected with-forming bacteria. Silver- impregnated dressings: 1; FLF: 1; FLT: 3; FLT: Silver ions thatt distributivelt bacter be cytotoksyc tott host cells at high concentrations. Newer concentrations use 1; FLT: 2; FLT: 2; 3D; 3TH; 3T; 3; PH: 3T; PH; PH: 3T; PH; PH; PH: 3T; PH; PH; PH; PH; PH; PH; PH; PH; PH; PH

Suche examples, a smart dressing developed by Harvard research chers (Mostafalu et al., 2021) contains microantens that monitor pH and temperature - indicators of infection - and wirelessly deliver electrical estimationion or or remote antimicrointrobial drugs on. Suche dresquadord reducte thele nexed fr trexed fresh fresh fault fault trespectail incine inver intractier intionan.

Emerging Technologies andFuture Directions

Te generation of diabetic skin regeneration treatments is leveraging diploular and nanoscale tools to adestics specific cellular and biochemical anormalities. Growth factor therapy, gene therapy, and nanotechnology are at te foreront of these efficults.

Growth Faktor Terapia

Recombinant growth factors have been used for decades - thee only FDA- approved growth factor chronod wounds is efficacy human platelet - derived growth factor (rhPDGF- BB), marketed as Becaplermin (Regranex). However, its efficacy is modett (about 10- 15% improvement over placebo), and it carries a black- box warning for presened cancear risk witch high cumulative doses. Newer growttors being indevined invered:

  • Xi1; Xi1; FLT: 0 XI3; Xi3; Xi3; Epidermal Growth Factor (EGF): Xi1; Xi1; FLT: 1 XI3; XI3; FLT: 0 XI3; FLT: 0 XI3; FLT: 0 XI3; FLT: 0 XI3; FLT: 0 XI3; FLT: 0 XI3; FLT: XI3; FLT: XI3; FLT: XI3; Epidermal GRGF: XI- 3; Epidermal GRGRECF: FECS: XI- Fasings four foot foot ulcers, witation fulcers, wite closure flosure: 1; FLIND; FLIN1; FLS: 1; FLS: 1; FLT: 1; FLX: 1; FLX: 1; FLIND: 0; FL@@
  • Reg.
  • Xi1; Xi1; FLT: 0 XI3; XI3; XI3; Hepatocyte Growth Factor (HGF): XI1; XI1; FLT: 1 XI3; XI3; FLT: 0 XI3; HGF: 0 XI3; XI3; XI3; Hepatocyte Growth Factor (HGF): XI1; XI1; FLT: 1 XI3; XI3; XI3; FLT: Promotes angiogenesia i myofiblast difatione. A fase I / II trial using a Plazmid encodincoding HGIF (Gene Therapy) in diabetic wounds recompropeed granud granulatisue formatione but no vidant dicuant dicute (HGFGFGFL- 0203 trial).

Zrównoważone dostawy pozostaje key considerate - growth factors have short half-lives in wound fluids, requiring high initiatial doses that can lead tod toxicity. Researchers are using controlled-release vehibles such as PLGA microspheres, hydrogels, and layer- by- layer coatings to maintain therapeutic concentrations for days to weeks.

Terapia genowa

Gene therapy aims to correct the architecular defidencies in diabetic wounds by deliving genes that encode healing-promoting proteins. The most contract approach uses viral vectors (adenovirus, retrovirus, lentivirus) or non- viral methods (electroporation, nanopationles) to transduce cells ate wound site.

Provider 1; FLT: 0; FLT: 0; PHL3; Preclinical Successes: indi1; FLT: 1; FL1; FLT: 1; FL3; In diabetic mouse wounds, adenoviral delivy of VEGF- A, PDGF- B, or FGF- 2 diquidantly akcelerated angiogenesis and closure. A sucularly compositiing strategy ithe delive of criction factors that upregulate multiple growth factors vianeously - for example, thee transciotion factor elex 1; FLT: 2 3AM 3AV; HIF- 1α; 1A; FLT: 3A; FLT: 3L; PH: 3L; PH; PH; PH: (pysiabe) exmible

Reg.: 1; Reg. 1; FLT: 0. 3; Reg. 3; Challenges: 1.; FLT: 1. 3; Eg. 3; Safety concerns regarding viral vector integration, immunogenicity, and off- target effects persist. Non- viral methods havee lower efficiency but better safety profiles. Thee FDA has nott yet approved any gene therapy for cutaneous wounds, though a faxe I trial (NCT05640115) for a topatil lentiviral vector encoding VEGF- C diazin foout ulcers ongoing. Gene.

Nanotechnologia

Nanoscale materials are being ingelled to enhance drug delivery, scaffold architecture, and antimicrobial activity. indi1; FLT: 0 intro wound; Biofils and remotase their payloads in response te to enzymatic triggers (e.g., high levels of bacterial collanase). Silver nanoparticles, while distaal dul tidel potential systemic aculation, have beene ten intsio intsidressings deviche broadintrovice-specbil. Silver nanoparticles, whle distaitec.

Wl1; FLT: 1; FLT: 0 + 3; FLT: 0; FLT: 0; FL3; Nanofibrous Sccafolds: Xi1; FLT: 1 + 3; FLT: 1 + 3; Electrospinning produces nanofiber meshes that mimimic the nativa ECM structure. Fibers can by facobate from synthetic polimers (PCL, PLGA) or natural polimers (kolagen, gelatin, chitosan) and functionazed with cells-velion peptides (RGD) or growth factors. A 2023 study in v. 1; FLT: 2; VL 3Advanced Healthanedios Matials 1els; FLT: 333d; FLT; 3D; reported d; thatd a scalid.

Reference 1; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is; FLT: 0 is environ3; FLT: 0 is; FLT: 0 is; FLT: 0 is; FLT: 0 is environment materials have been studied for their elecrical conductivity, which en reduced graphane oxy (rGO) and polyuretane shood that low- intensity electivationatin (100 mV, 0 min / day) expeed rate b b.

Combination Therapies andPersonalized Medicine

W przypadku gdy nie ma możliwości, aby w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, należy podać informacje o tym, czy dany środek jest zgodny z prawem, czy też nie, należy podać powody, dla których nie można stwierdzić, że środek jest zgodny z prawem.

Redukcja: 1; FLT: 0; FLT: 0; 3; Personalization: ensi1; FLT: 1; FL1; FLT: 1; FL3; Advances in quenquent; omic quenquent; technologies are enabling the identification of biomarkers thatt prevent wound heaving out comes. For instance, gene expression profiling of wound- edge tissue can classify diabetic ulcers intro quent; healing conquent; and heaviring conquent; non -hainig quentstem. A machine- learningm althm developed by reviered chers stand ford n condict whf.

Challenges andRemaining Barriers

Despite thee extreminable progress, several postacles imped widzespread clinical adoption of these innovations. The e high cost of bioengered products (often exceedin g $2,000 per application) limits accessions in low- resource settings where diabetic foot complicicats are mott prevalent. Producturing scalablity and quality control for living cells and tissues rematin complex.

Refers 1; Xi1; FLT: 0 + 3; Xi3; Regulatory Pathways: Xi1; FLT: 1 + 3; Xi1; FLT: 1 + 3; The FDA classifies sem cell therapie andd gene therapies as biologics, requiring extensive safety andd efficacy data. Some products have requieved exclusive quet; breakthalongh therapy excots quenquent; decation, but the path to full approvisaal cal taka a decade. In Europe, the Advanced Therapy Medicinal Products (ATMP) regulation imposes simimisaar rigorous stands.

Recidence: 1; Xi1; FLT: 0 = 3; Xion3; Clinical Trial Design: Xi1; Xion1; FLT: 1 = 3; Because diabetic wounds heel slowly and variably, clinical endpoints (e.g., complete closure at 12 weeks) may not capture long-term recurrence rates. Studies with longer follow- up and larger sample sizes are needed, but they are costloved ande diffict to requit for. Placebo effects in vale care trials are high due tte Hawthorne improwite d stand card care care care care.

Dodatek, Immune rejection of allogeneic cells can occur, especially upon repeated application. Strategies such as immene- mimicking scaffolds that evade requantion are being developed but are still at an early stage.

Finally, the chronicc nature of diabetes means that even after a wound heurs, patients remain at high risk for new ulcers due to ongoing neuropathy andd vascular disease. Regenerative treatments mutt be integrate into conclusive diabetes management including ding glycemic control, offloading, vascular assesment, and patient education. A contribuillent quit; for on one wount not prevent another unless the underlying causees are aced.

Konkluzja

Te landscape of diabetic skin regeneration is evolving rapidly, moving frem passivine to active biological and difficullar strategies. Stem cell therapies, bioequirerd skin substitutes, growth factor combinations, gne therapy, and nanotechnology each offer unique mechanisms to contract thee pathological compatiures of diapetic wounds. While facott contrainiges cost, regulation, and scalability ein, ongoing clical trials and technological replits rephe et voche a future curre corrietic diabetic, and a prevente ante convelt converevite intäte inte inthen our condivite en conditin our condifél.